Novartis Bags Another Bolt-On With Cadent Buy

Pays $210m Upfront For Cognitive Disorder Biotech

 
• By Kevin Grogan
  
Mergers
Novartis sees Cadent as a good strategic fit • Source: Archive

More from Deals

More from Business